glp-1 news november 25 2025 Weight Loss Drug Enforcement in 2025: State Attorneys General Step into a Growing Regulatory Gap Novo cuts GLP-1 prices 70%,
Description
It is a serious, chronic, progressive disease tied to type 2 diabetes, cardiovascular disease, hypertension, stroke, fatty liver disease, sleep apnea, kidney disease, certain cancers, joint disease, depression, reduced mobility, and a lower quality of life
What you need to know about popular weight loss medications and how direct primary care can help you meet your goals.
Among the top blockbuster launches are the GLP-1 brands launched since 2018, as well as transformative first-in-class treatments like Harvoni (Hepatitis C) and Ocrevus (multiple sclerosis)
A bipartisan bill soon to be introduced in the state Legislature seeks to decrease the cost of GLP-1 drugs in Pennsylvania
